Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie has shown strong growth, especially in immunology and oncology, with Skyrizi and Rinvoq driving impressive sales and long-term growth potential. Despite Humira's patent loss, AbbVie has managed a "soft landing" and continues to innovate, particularly in neuroscience and oncology. The company offers a solid dividend with a 51% payout ratio and consistent growth, making it attractive for conservative investors seeking income and growth.

Why AbbVie Remains One Of My Favorite Dividend Growers

Altria

A recession is looming. Despite the S&P 500 nearing its all-time high, the yield curve inverted and the

2 Stocks to Buy Now Before a Stock Market Crash

More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016 NORTH CHICAGO, Ill. , Aug. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic, inflammatory diseases as they pursue higher education.

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases

SkinMedica®, by the makers of BOTOX® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE® Technology for deeper hydration IRVINE, Calif. , Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica® has been at the forefront of science-based skincare solutions, and today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of its next generation hydration product: SkinMedica® HA5® Hydra Collagen Replenish + Restore Hydrator.

SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator

Cigna

Cigna said on Monday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

ATLANTA--(BUSINESS WIRE)---- $ABBV #505b2_pathway_for_FDA_approval--Alzamend Neuro Issues Letter to Stockholders; recently announced partnership with Mass. General Hospital for 5 Phase II clinical trials of AL001.

Alzamend Neuro Issues Letter to Stockholders

Abbott Labs

Archer-Daniels-Midland Company

Cincinnati Financial

Trump Media & Technology Group Corp

Con Ed

Emerson Electric

Federal Realty Investment Trust

Hormel Foods

Illinois Tool Works

Johnson & Johnson

Coca-Cola

Kenvue

Lancaster Colony

Lowe's

PepsiCo

Procter & Gamble

Parker-Hannifin

PPG Industries

Target

Walmart

The former president's recent regulatory filing disclosed positions in 21 Dividend Kings. Most of these stocks underperformed the S&P 500 over the last five years.

Donald Trump Owns These 21 Dividend Kings. Should You?

Amgen

Abbott Laboratories is a Dividend King with a diverse business. Amgen offers a high dividend yield plus a track record of innovation.

3 Unstoppable Dividend Stocks to Buy Right Now

Merck

We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV.

Is Merck Stock A Better Pick Over AbbVie?

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapy FL is an incurable form of non-Hodgkin's lymphoma (NHL), with about 13,000 estimated cases in Western Europe alone each year1 NORTH CHICAGO, Ill. , Aug. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy.

European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Alzamend Neuro

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it is partnering with Massachusetts General Hospital as its contract research organization (“CRO”) to conduct first of its kind Phase II clinical study of AL001.

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Enbridge

Realty Income Corp

AbbVie is a Dividend King that's poised for future growth. Enbridge offers an ultra-high dividend yield and is expanding into more areas of the energy sector.

3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More

Novo Nordisk

Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.

These 3 Healthcare Companies Had the Top-Selling Drugs Last Year

Prologis

Verizon

AbbVie enables retirees to profit from both its dividend payouts and its promising growth opportunities. Verizon has a safe high-yielding dividend, which the company has been growing steadily in recent years.

3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income

Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future.

Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Visa

Everything looked like it was coming undone last week. As recession fears gripped the market, the S&P 500 tumbled 3% in a single day.

The 3 Best Stocks to Buy to Survive Another S&P 500 Crash

Eli Lilly

Pfizer

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.

3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View

24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.

Prediction: Abbvie's Dividend Payouts Will Increase in 2025

ATLANTA--(BUSINESS WIRE)---- $ABBV #21_million_Americans_afflicted_with_MDD--Alzamend Neuro Partners with Mass. General Hosp. for Phase II Clinical Trial of AL001, a Next-Generation Lithium Drug for Major Depressive Disorder.

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Constellation Energy Corp

Ford Motor Company

Welltower

The Federal Reserve is widely expected to start cutting interest rates at its next meeting and a lower federal funds rate could benefit these five stocks.

Best Stocks to Buy for a Fed Rate Cut

Bristol-Myers

Gilead Sciences

AbbVie offers reliable income and solid growth prospects. Bristol Myers Squibb is a stable dividend stock to buy and hold.

3 Stocks Retirees Should Absolutely Love

Apple

Ares Capital

Home Depot

Lockheed Martin

Microsoft

Vici Properties

Times of higher uncertainty and elevated market volatility can provide investors with excellent opportunities to start building a dividend portfolio. The dividend portfolio I will present in today's article provides investors with broad diversification across sectors, with no sector accounting for more than 18% of the overall portfolio. This dividend portfolio delivers a Weighted Average Dividend Yield [TTM] of 3.90% and a 5-year Weighted Average Dividend Growth Rate of 8.69%.

Building A $100,000 Dividend Portfolio With 3 ETFs And 3 Stocks

American Tower

10,000 boomers are reaching retirement age every day. The 4% rule for retirement withdrawals may not always work due to sequence risk and market fluctuations. Building a dividend income snowball can provide a more stable retirement income, with 2 high-yielding recession-proof stock picks recommended.

2 High Yielding Recession Proof Dividend Picks For A Massive Income Snowball

News for AbbVie Stock (ABBV)